Drug Sales Trends for AGGRENOX

Annual Sales Revenues and Units Sold for AGGRENOX

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
AGGRENOX			2021
AGGRENOX			2020
AGGRENOX			2019

Market Analysis and Sales Projections for Aggrenox

Overview of Aggrenox

Aggrenox, a combination drug containing aspirin and extended-release dipyridamole, is prescribed to lower the risk of stroke in patients who have had a mini-stroke (transient ischemic attack or TIA) or a stroke due to a blood clot. Here’s a detailed analysis of the market and sales projections for Aggrenox.

Current Market Status

As of recent years, the market for Aggrenox has faced significant challenges. The launch of generic versions of Aggrenox has substantially impacted its sales. For instance, Teva Pharmaceutical Industries launched generic Aggrenox capsules in the United States in 2015, which had annual sales of approximately $457 million at that time[4].

Impact of Generic Competition

The introduction of generic aspirin and extended-release dipyridamole capsules has led to a decline in the sales of the branded version of Aggrenox. Generic competition often results in lower prices and increased market share for the generic alternatives, which can erode the market share and revenue of the original branded product.

Market Trends and Forecast

The global ischemic stroke market, which includes Aggrenox, is expected to see mixed trends. While the overall disease burden of ischemic stroke is increasing, making the market larger, the specific sales of Aggrenox are projected to decline. This decline is largely due to the increasing uptake of generic clopidogrel and other generic alternatives, similar to what is happening with Plavix[1].

Sales Projections

Given the current market dynamics, the sales projections for Aggrenox are not optimistic. Here are some key points:

• Declining Sales: The sales of Aggrenox are expected to continue declining as generic versions gain more market share. This trend is similar to what is observed with other drugs like Plavix, which is losing market share due to generic clopidogrel[1].
• Market Share Erosion: The launch of generic Aggrenox capsules by companies like Teva has already led to significant market share erosion. This trend is likely to continue, further reducing the sales of the branded version.
• Competition from Other Treatments: The ischemic stroke market is also seeing strong uptake of other treatments, such as Activase (alteplase), which is prescribed to 65% of ischemic stroke patients in the US, Japan, and five major EU markets who receive thrombolytic therapy. This competition further diminishes the market share of Aggrenox[1].

Epidemiology and Disease Burden

Despite the declining sales of Aggrenox, the overall burden of ischemic stroke is increasing. Stroke is the second most common cause of death and a major cause of disability worldwide. The majority of strokes are ischemic, and this trend is expected to continue, which could potentially sustain some level of demand for stroke prevention medications like Aggrenox, albeit at a reduced level due to generic competition[1].

Prescribing Trends

Prescribing trends for Aggrenox are also shifting. With the availability of generic alternatives, healthcare providers are increasingly opting for these cost-effective options. This shift is driven by both economic factors and the equivalent efficacy of generic drugs, further reducing the prescription rates for branded Aggrenox[4].

Conclusion

In summary, the sales projections for Aggrenox are bleak due to the significant impact of generic competition. While the overall market for ischemic stroke treatments is growing, the specific sales of Aggrenox are expected to decline as generic versions continue to gain market share.

Key Takeaways

• Generic Competition: The launch of generic Aggrenox capsules has led to a substantial decline in the sales of the branded version.
• Market Trends: The global ischemic stroke market is growing, but Aggrenox sales are expected to decline due to generic competition.
• Prescribing Trends: Healthcare providers are increasingly opting for generic alternatives, reducing the prescription rates for branded Aggrenox.
• Epidemiology: The overall burden of ischemic stroke is increasing, but this does not translate to increased sales for Aggrenox due to generic competition.

FAQs

Q: What is Aggrenox used for?

Aggrenox is used to lower the risk of stroke in people who have had a mini-stroke (transient ischemic attack or TIA) or a stroke due to a blood clot.

Q: Why are Aggrenox sales declining?

Aggrenox sales are declining due to the introduction of generic versions of the drug, which offer a cost-effective alternative and have eroded the market share of the branded version.

Q: How does generic competition affect Aggrenox sales?

Generic competition leads to lower prices and increased market share for the generic alternatives, resulting in reduced sales and revenue for the branded Aggrenox.

Q: What other treatments are competing with Aggrenox in the ischemic stroke market?

Other treatments like Activase (alteplase) are gaining strong uptake in the ischemic stroke market, further reducing the market share of Aggrenox.

Q: What is the impact of the increasing disease burden of ischemic stroke on Aggrenox sales?

Despite the increasing disease burden of ischemic stroke, the sales of Aggrenox are expected to decline due to the dominance of generic alternatives in the market.

Sources

1. ResearchAndMarkets.com, "Global Ischemic Stroke Market and Forecast Analysis to 2024 - Activase will Continue to Experience Strong Uptake while Aggrenox and Plavix Face Declining Sales"
2. Patsnap Synapse, "Amgen Announces Q2 2024 Financial Results"
3. Verified Market Research, "In-Depth Industry Outlook: Aspirin Market Size & Forecast"
4. Teva Pharmaceutical Industries, "Teva Launches Generic Aggrenox® Capsules in the United States"
5. Amgen, "AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS"